Whistleblowers in the pharmaceutical industry: tragic hero, black sheep or alter ego ?
Whistleblowing is the practice of disclosing, by an employee, illegal misconduct and moral wrong doing in business. A transdisciplinary approach of whistleblowing allows better understanding of its causes and consequences. Therefore, a thorough analysis of the most common deviancies is worthwhile. We studied whistleblowing in the specific economic and ethical issues of pharmaceutical industry. We drew an overview from whistleblower’s ethics through transgression to compliance officer’s ethics through business standards. We propose to overcome this dialectic polarization by taking into account self-empowerment industry insider’s ethics through customer’s alterity.
|Date of creation:||25 Feb 2014|
|Date of revision:|
|Contact details of provider:|| Postal: |
Phone: 33 1 53 63 36 00
Web page: http://www.ipag.fr
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Sergio Sismondo, 2007. "Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry?," Working Papers id:1254, eSocialSciences.
- Richard Nielsen, 2013. "Whistle-Blowing Methods for Navigating Within and Helping Reform Regulatory Institutions," Journal of Business Ethics, Springer, vol. 112(3), pages 385-395, February.
When requesting a correction, please mention this item's handle: RePEc:ipg:wpaper:2014-118. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Ingmar Schumacher)
If references are entirely missing, you can add them using this form.